---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021847"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T07:49:52.638110+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics Q3 net loss $142.3M, cash $896M; FDA AdCom Dec 13 for omecamtiv mecarbil

## Summary
- Net loss of $142.3M ($1.52/share) vs $76.1M ($0.95) in Q3 2021; revenue $2.5M, down from $5.4M.
- Cash, equivalents and investments $896.2M; net proceeds of $523.6M from 3.50% convertible notes due 2027.
- FDA Advisory Committee to review omecamtiv mecarbil NDA on Dec 13, 2022; PDUFA target Feb 28, 2023.
- SEQUOIA-HCM (aficamten Phase 3) enrollment ongoing; results expected in 2H 2023.
- COURAGE-ALS (reldesemtiv Phase 3) continues after first interim analysis; enrollment to complete 1H 2023.

## SEC filing metadata
- accession: 0000950170-22-021847
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017022021847/0000950170-22-021847-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017022021847/cytk-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021847
- JSON: https://secwatch.observer/filing/0000950170-22-021847.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021847.txt

## Key facts
- Earnings Releases
  CYTOKINETICS INC reported third quarter of 2022 results: net income Net loss for the third quarter was $142.3 million, EPS $1.52 per share.
  - Period: third quarter of 2022
  - Net income: Net loss for the third quarter was $142.3 million
  - EPS: $1.52 per share
  - Result: reported results
  source text: Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the third quarter of 2022. Net loss for the third quarter was $142.3 million, or $1.52 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061983/000095017022021847/0000950170-22-021847-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.